KEROS THERAPEUTICS INC (KROS) Stock Price, Forecast & Analysis
NASDAQ:KROS • US4923271013
KROS Key Statistics, Chart & Performance
The current stock price of KROS is 16.58 USD. In the past month the price decreased by -13.91%. In the past year, price increased by 60.66%.
KROS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to KROS. When comparing the yearly performance of all stocks, KROS is one of the better performing stocks in the market, outperforming 85.38% of all stocks.
KROS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to KROS. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
KROS Financial Highlights
Over the last trailing twelve months KROS reported a non-GAAP Earnings per Share(EPS) of 1.54. The EPS increased by 129.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 26.12% | ||
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| Debt/Equity | 0 |
KROS Forecast & Estimates
16 analysts have analysed KROS and the average price target is 23.97 USD. This implies a price increase of 44.57% is expected in the next year compared to the current price of 16.58.
For the next year, analysts expect an EPS growth of 143.7% and a revenue growth 40853.1% for KROS
KROS Ownership
KROS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KROS
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 82 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Company Info
KEROS THERAPEUTICS INC
1050 Waltham Street, Suite 302
Lexington MASSACHUSETTS 02421 US
CEO: Jasbir Seehra
Employees: 169
Phone: 18004831140
KEROS THERAPEUTICS INC / KROS FAQ
What does KROS do?
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 82 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
What is the current price of KROS stock?
The current stock price of KROS is 16.58 USD. The price decreased by -0.18% in the last trading session.
Does KROS stock pay dividends?
KROS does not pay a dividend.
What is the ChartMill technical and fundamental rating of KROS stock?
KROS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the growth outlook for KEROS THERAPEUTICS INC?
The Revenue of KEROS THERAPEUTICS INC (KROS) is expected to grow by 40853.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for KEROS THERAPEUTICS INC?
KEROS THERAPEUTICS INC (KROS) will report earnings on 2026-03-04, after the market close.
Can you provide the ownership details for KROS stock?
You can find the ownership structure of KEROS THERAPEUTICS INC (KROS) on the Ownership tab.